Document and Entity Information |
Jul. 10, 2026 |
|---|---|
| Document And Entity Information [Line Items] | |
| Document Type | 8-K/A |
| Document Period End Date | Jul. 10, 2026 |
| Entity Registrant Name | Silence Therapeutics plc |
| Entity Incorporation State Country Code | X0 |
| Entity File Number | 001-39487 |
| Entity Tax Identification Number | 00-0000000 |
| Entity Address Address Line 1 | 12 Hammersmith Grove |
| Entity Address City Or Town | London |
| Entity Address Country | GB |
| Entity Address Postal Zip Code | W6 7AP |
| Country Region | 44 |
| City Area Code | 20 |
| Local Phone Number | 3457 6900 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Entity Emerging Growth Company | false |
| Amendment Flag | true |
| Amendment Description | This Amendment No. 1 to the Current Report on Form 8-K supplements and amends Item 5.02 of the Current Report on Form 8-K filed on December 15, 2025 (the “Original Form 8-K”) to disclose information regarding material modifications to a material compensatory plan, contract or arrangement as to which a named executive officer of the registrant participates that were effected pursuant to an agreement entered into subsequent to the filing of the Original Form 8-K. No other changes have been made to the Original Form 8-K. |
| Entity Central Index Key | 0001479615 |
| ADR [Member] | |
| Document And Entity Information [Line Items] | |
| Security 12b Title | American Depositary Shares, each representing 3 ordinary shares, nominal value £0.05 per share |
| Trading Symbol | SLN |
| Security Exchange Name | NASDAQ |
| Common Stock [Member] | |
| Document And Entity Information [Line Items] | |
| Security 12b Title | Ordinary share, nominal value £0.05 per share |
| Security Exchange Name | NASDAQ |
| No Trading Symbol Flag | true |